Monitoring Cholesterol Levels: Measurement Error or True Change?
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cholesterol level monitoring is a common clinical activity, but the optimal monitoring interval is unknown and practice varies. OBJECTIVE: To estimate, in patients receiving cholesterol-lowering medication, the variation in initial response to treatment, the long-term drift from initial response, and the detectability of long-term changes in on-treatment cholesterol level ("signal") given short-term, within-person variation ("noise"). DESIGN: Analysis of cholesterol measurement data in the LIPID (Long-Term Intervention with Pravastatin in Ischaemic Disease) study. SETTING: Randomized, placebo-controlled trial in Australia and New Zealand (June 1990 to May 1997). PATIENTS: 9014 patients with past coronary heart disease who were randomly assigned to receive pravastatin or placebo. MEASUREMENTS: Serial cholesterol concentrations at randomization, 6 months, and 12 months, and then annually to 5 years. RESULTS: Both the placebo and pravastatin groups showed small increases in within-person variability over time. The estimated within-person SD increased from 0.40 mmol/L (15 mg/dL) (coefficient of variation, 7%) to 0.60 mmol/L (23 mg/dL) (coefficient of variation, 11%), but it took almost 4 years for the long-term variation to exceed the short-term variation. This slow increase in variation and the modest increase in mean cholesterol level, about 2% per year, suggest that most of the variation in the study is due to short-term biological and analytic variability. Our calculations suggest that, for patients with levels that are 0.5 mmol/L or more (> or =19 mg/dL) under target, monitoring is likely to detect many more false-positive results than true-positive results for at least the first 3 years after treatment has commenced. LIMITATIONS: Patients may respond differently to agents other than pravastatin. Future values for nonadherent patients were imputed. CONCLUSION: The signal-noise ratio in cholesterol level monitoring is weak. The signal of a small increase in cholesterol level is difficult to detect against the background of a short-term variability of 7%. In annual rechecks in adherent patients, many apparent increases in cholesterol level may be false positive. Independent of the office visit schedule, the interval for monitoring patients who are receiving stable cholesterol-lowering treatment could be lengthened.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., Pasternak, R. C., Smith, S. C., & Stone, N. J. (2004) · Circulation · doi:10.1161/01.cir.0000133317.49796.0e · Cited by 6,902
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Comparing methods of measurement: why plotting difference against standard method is misleading
Bland, J. M., & Altman, D. G. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91748-9 · Cited by 2,343
Assessing Medication Adherence in the Elderly: Which Tools to Use in Clinical Practice?
MacLaughlin, E. J., Raehl, C. L., Treadway, A. K., Sterling, T. L., Zoller, D. P., & Bond, C. A. (2005) · Drugs & Aging · doi:10.2165/00002512-200522030-00005 · Cited by 363
Cited by
Wanner, C., the Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members, & Tonelli, M. (2014) · Kidney International · doi:10.1038/ki.2014.31 · Cited by 649
Heneghan, C., Ward, A., Perera, R., Bankhead, C., Fuller, A., Stevens, R., Bradford, K., Tyndel, S., Alonso-Coello, P., Ansell, J., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61294-4 · Cited by 372
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
Palmer, S. C., Navaneethan, S. D., Craig, J. C., Johnson, D. W., Perkovic, V., Hegbrant, J., & Strippoli, G. F. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007784.pub2 · Cited by 331
Lipid management in patients with chronic kidney disease
Ferro, C. J., Mark, P. B., Kanbay, M., Sarafidis, P., Heine, G. H., Rossignol, P., Massy, Z. A., Mallamaci, F., Valdivielso, J. M., Malyszko, J., et al. (2018) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0072-9 · Cited by 273
Kones, R. (2011) · Drug Design, Development and Therapy · doi:10.2147/dddt.s14934 · Cited by 259
Metadata
- Authors
- Glasziou, P. P., Irwig, L., Heritier, S., Simes, R. J., Tonkin, A., & for the LIPID Study Investigators
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2008-05-06
- Volume
- 148
- Issue
- 9
- Pages
- 656-661
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2097618561
- Cited by
- 122
- References
- 4
- FWCI
- 11.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Monitoring Cholesterol Levels: Measurement Error or True Change? https://app.cochat.ai/papers/10.7326/0003-4819-148-9-200805060-00005
- The paper
- Glasziou, P. P., Irwig, L., Heritier, S., Simes, R. J., Tonkin, A., & for the LIPID Study Investigators. (2008). Monitoring Cholesterol Levels: Measurement Error or True Change? Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-148-9-200805060-00005
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.